Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-9001A Phase Ia in Healthy Subjects
NCT05278611Phase 1Unknown
- Sponsor
- Chengdu Easton Biopharmaceuticals Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neuropathic pain and cancer pain comparing EP-9001A with Placebo (2 arms). Primary endpoints: Number and severity of Adverse Events and Maximum Tolerated Dose. Status: unknown.
02
Drugs
EP-9001A
03
Conditions
neuropathic paincancer pain
Beyond the preview
Go deeper on NCT05278611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278611.